HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Suspends SK-II Sales in China Over Impurities Uproar

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble is suspending sales of its SK-II skin care and cosmetics brand in mainland China until authorities there clarify their stance in regards to the detection of certain impurities in the line

You may also be interested in...



P&G Beauty Grows On Fine Fragrances; Blades, Razors Drive Sales Overall

Prestige fragrance sales helped drive eight percent growth in Procter & Gamble's beauty business to $5.88 billion for the firm's fiscal year 2007 second quarter, ended Dec. 31, 2006, the company says

P&G Beauty Grows On Fine Fragrances; Blades, Razors Drive Sales Overall

Prestige fragrance sales helped drive eight percent growth in Procter & Gamble's beauty business to $5.88 billion for the firm's fiscal year 2007 second quarter, ended Dec. 31, 2006, the company says

P&G Q1 Beauty Sales Advance On Performance Of Olay, Pantene

Procter & Gamble beauty division revenues increased 11% to $5.6 bil. for the first quarter of fiscal year 2007 (ended Sept. 30), fueled by growth across all categories and the addition of Gillette products, the company reported in an Oct. 31 earnings release

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel